Floatz logo

Universal Bcma Car-T

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Xuanwu Hospital, BeijingCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Chronic Inflammatory Demyelinating Polyradiculoneuropathy cohort.

Asset / SponsorPhaseRating
AMIFAMPRIDINE
National Center for Research Resources (NCRR)
Phase 3BB
HUMAN IMMUNOGLOBULINS
National Center for Research Resources (NCRR)
Phase 3BB
i10e
Laboratoire français de Fractionnement et de Biotechnologies
Phase 3B
Anti-Thymoglobulin, Rabbit
Fred Hutchinson Cancer Center
Phase 2CCC
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2CCC

View all 18 →

Same molecule, other indications

Universal Bcma Car-T is also rated in:

neuromyelitis opticaDormant
C
Indicative ·
39 / 100
View asset →
myasthenia gravisDormant
C
Indicative ·
39 / 100
View asset →
multiple sclerosisDormant
C
Indicative ·
34 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →